On Tuesday, Travere Therapeutics Inc (NASDAQ: TVTX) opened higher 3.14% from the last session, before settling in for the closing price of $34.76. Price fluctuations for TVTX have ranged from $12.91 to $37.50 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -3.34%. Company’s average yearly earnings per share was noted 89.91% at the time writing. With a float of $87.73 million, this company’s outstanding shares have now reached $89.46 million.
Travere Therapeutics Inc (TVTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Travere Therapeutics Inc is 1.95%, while institutional ownership is 116.69%. The most recent insider transaction that took place on Dec 15 ’25, was worth 104,760. In this transaction SVP, CHIEF ACCOUNTING OFFICER of this company sold 2,910 shares at a rate of $36.00, taking the stock ownership to the 45,635 shares. Before that another transaction happened on Dec 15 ’25, when Company’s Officer proposed sale 2,910 for $36.00, making the entire transaction worth $104,760.
Travere Therapeutics Inc (TVTX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.47 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.38) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 89.91% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Check out the current performance indicators for Travere Therapeutics Inc (TVTX). In the past quarter, the stock posted a quick ratio of 2.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.08, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach 0.80 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Looking closely at Travere Therapeutics Inc (NASDAQ: TVTX), its last 5-days average volume was 1.5 million, which is a drop from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 58.90%.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 92.66%, which indicates a significant increase from 59.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.50 in the past 14 days, which was higher than the 1.33 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.24, while its 200-day Moving Average is $21.68. However, in the short run, Travere Therapeutics Inc’s stock first resistance to watch stands at $36.60. Second resistance stands at $37.34. The third major resistance level sits at $38.53. If the price goes on to break the first support level at $34.67, it is likely to go to the next support level at $33.48. Now, if the price goes above the second support level, the third support stands at $32.74.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
There are currently 89,472K shares outstanding in the company with a market cap of 3.21 billion. Presently, the company’s annual sales total 233,180 K according to its annual income of -321,550 K. Last quarter, the company’s sales amounted to 164,860 K and its income totaled 25,710 K.
